Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Down 60.0% in April

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 14,050 shares, a decline of 60.0% from the April 15th total of 35,087 shares. Based on an average daily volume of 12,279 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.9% of the company’s shares are sold short.

Aethlon Medical Stock Performance

AEMD traded down $0.01 on Friday, reaching $2.13. 5,460 shares of the company’s stock were exchanged, compared to its average volume of 51,062. The company has a market cap of $3.35 million, a price-to-earnings ratio of -0.15 and a beta of 1.50. Aethlon Medical has a twelve month low of $1.36 and a twelve month high of $34.05. The company’s 50 day moving average is $2.15 and its 200-day moving average is $2.82.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Thursday, February 12th. The medical equipment provider reported ($2.45) EPS for the quarter, missing the consensus estimate of ($2.01) by ($0.44). Sell-side analysts forecast that Aethlon Medical will post -9.94 EPS for the current year.

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 36.57% of Aethlon Medical at the end of the most recent reporting period. Institutional investors own 1.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.